IP Library Granted Patent US 6,951,639
Granted Patent B2
US 6,951,639 · App. 10/118,430 · Granted Oct 4, 2005

1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,951,639
App. No.
10/118,430
Granted
Oct 4, 2005
Kind
B2
Abstract

1,4,7,10-Tetraazacyclodedecane butyltriols of general formula I A in which R 1 means hydrogen or a metal ion equivalent independent of one another and R 2 means a butyltriol radical as well as their salts with organic or inorganic bases or amino acids are valuable pharmaceutical agents.

Claims (10)

1. A method of performing in vivo NMR spectroscopy in a patient comprising administering a compound as a susceptibility agent which has the formula I A

in which

each R 1 is hydrogen or a metal ion equivalent, independent of one another and

R 2 is butyltriol

or a salt thereof with an organic or inorganic base or an amino acid, and at least two of the substitutens R 1 are metal ion equivalents.

2. A method of radiation therapy of a patient comprising administering as a photon and electron emitting agent, a compound which has the formula I A

in which

each R 1 is hydrogen or a metal ion equivalent, independent of one another and

R 2 is butyltriol

or a salt thereof with an organic or inorganic base or an amino acid, and at least two of the substitutens R 1 are metal ion equivalents.

Assignments (2)
CHANGE OF NAME Recorded Jul 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030719/0150 →
CHANGE OF NAME Recorded Nov 14, 2007
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 020156/0001 →